Artemisinin-based combination therapy for ... - The Cochrane Library

(Continued)
Harms: Early vomiting
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1 Bonnet 2004 GIN; Djimde 2004 MLI; Guthmann 2003 AGO; Hamour 2003 SDN; Kayentao 2006 MLI; Swarthout 2004 ZAR;
Van den Broek 2004 ZAR.
2 Serious limitations: Allocation concealment was assessed as ’low risk of bias’ in only one trial. Only one trial had adequate blinding of
laboratory staff.
3 No serious inconsistency: Heterogeneity was low.
4 Trials were conducted in a variety of African countries (Guinea, Mali, Angola, DRC) and transmission intensities in children aged 6
to 59 months.
5 Serious imprecision: The 95% CI of the pooled estimate includes appreciable benefit with ASAQ and crosses the line of no effect.
6 Very serious inconsistency: Heterogeneity was high (I 2 = 88%) with some trials showing benefit with AS+AQ and some with AS+SP.
7 Very serious imprecision: Data were not pooled due to high heterogeneity.
8 No difference was shown in gametocyte carriage at day three or seven.
9 Serious limitations: No trial adequately described an allocation concealment procedure.
10 No serious inconsistency: Heterogeneity was low.
11 Very serious imprecision: The 95% CI of the pooled estimate is wide including appreciable benefit or harm of each drug over the
other.
Is Artesunate plus amodiaquine superior to Amodiaquine plus sulfadoxine-pyrimethamine for treating uncomplicated malaria?
Patient or population: Patients with uncomplicated malaria
Settings: Africa
Intervention: Artesunate plus amodiaquine
Comparison: Amodiaquine plus sulfadoxine-pyrimethamine
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
261